Skip to main content

Year: 2022

Global Halal Food Market to Generate $3,907.8 Billion by 2028 | Manufacturers Are Rushing to Get Halal Certification to Capitalize on Halal Trend

Global halal food market is valued at USD 1,977 billion in 2021, and it is expected to attain a value of USD 3,907.8 billion by 2028, at a CAGR of 11.25% over the forecast period (2022-2028). Westford, USA, Nov. 17, 2022 (GLOBE NEWSWIRE) — Islamic dietary law mandates that meat, poultry, and seafood be supplied halal, meaning that they must meet certain religious requirements concerning the way they were killed. The Islamic faith is the second most practicing religion in the world after Christianity, with approximately 1.98 billion followers worldwide and over 26 Muslim countries. There are two main reasons for the growth in demand for halal food market: First, Muslims are increasingly looking to follow a stricter diet that adheres to their religious beliefs. Second, Halal certification has become an important marketing tool for...

Continue reading

VILLE PELTONEN APPOINTED GROUP CFO AT ROBIT PLC

ROBIT PLC        STOCK EXCHANGE RELEASE         17 NOVEMBER 2022 AT 2.20 P.M.                      VILLE PELTONEN APPOINTED GROUP CFO AT ROBIT PLC Ville Peltonen (M.Sc. Economics) has been appointed Group CFO at Robit Plc as of 17 November 2022. Peltonen has worked as an interim CFO since 16 March 2022 as the company’s former Group CFO, Arto Halonen was appointed the company’s Group CEO. Prior to holding the interim CFO position, Peltonen worked as a Group Controller at Robit Plc since 2020. Peltonen is also a member of the company’s Management Team.   ROBIT PLCArto Halonen Further information:Arto Halonen, Group CEO+358 40 028 0717arto.halonen@robitgroup.com Distribution:Nasdaq Helsinki LtdKey mediawww.robitgroup.com Robit is the expert focused on high quality drilling consumables for mining and construction markets globally to help...

Continue reading

Global Plastic Market to Touch Valuation of $752.16 Billion by 2028 | Biodegradable Plastic Could to Be Future and Offer Revenue Opportunity of $58 Billion

Global plastic market was valued at USD 599.25 billion in 2021 and it is expected to reach at USD 752.16 billion by 2028, at a CAGR of 3.3% over the forecast period (2022-2028). Westford, USA, Nov. 17, 2022 (GLOBE NEWSWIRE) — Global plastic market is expected to be worth $752.16 billion by 2028, an increase of over 25% from 2021. The key drivers behind this growth are the rising demand for plastics in many industries such as automotive, food and beverage, packaging, and furniture as well as improvements in efficiency and productivity that have led to increased output. SkyQuest predicts that the automotive and construction equipment markets will account for a majority of plastic manufacturing sales over the next decade. These two markets are expected to experience significant growth owing to their need for a variety of plastic products,...

Continue reading

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Achieved proof of concept and identified a responder population In view of the small population, the Company will pause enrollment in the BRILLIANCE trial and seek to identify a collaboration partner to continue development of EDIT-101 Company to host a webinar today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced clinical data from the Phase 1/2 BRILLIANCE trial of EDIT-101, an in vivo CRISPR/Cas9 genome editing medicine in a Company-sponsored webinar. EDIT-101 is under development for the treatment of blindness due to...

Continue reading

PERTTU AHO APPOINTED VP DOWN THE HOLE AT ROBIT PLC

ROBIT PLC        STOCK EXCHANGE RELEASE         17 NOVEMBER 2022 AT 2.15 P.M.                      PERTTU AHO APPOINTED VP DOWN THE HOLE AT ROBIT PLC Perttu Aho (b. 1968, B.B.A.) has been appointed responsible for the Down the Hole business unit at Robit Plc. He will also be a member of the company’s Management Team. His position will be VP Down the Hole. Aho joined Robit in 2020 and since then he has been successfully leading the company’s Halco brand. Aho will start in his new role immediately. The company’s current VP Down the Hole, Adam Baker has decided to leave his tasks as the VP DTH and member of the Management Team to pursue other opportunities outside the company. Baker’s employment at Robit Plc ends on 31 December 2022. Robit Plc thanks Baker for his excellent cooperation and wishes all the best in his future duties. ROBIT...

Continue reading

uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022

~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov. 17, 2022 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will host a Virtual Research & Development Event on Tuesday, November 29, 2022 from 8:30 a.m. to 10:30 a.m. EST. The event will focus on the unmet medical need of patients with refractory temporal lobe epilepsy (rTLE) and the Company’s preclinical gene therapy candidate for rTLE, AMT-260, that is anticipated to enter clinical development in 2023. Ellen Bubrick, MD, associate chair of Neurology, Quality and Safety and director of the Epilepsy Surgery Program at Brigham and Women’s Hospital in Boston, Mass. and assistant professor...

Continue reading

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care SALT LAKE CITY, Nov. 17, 2022 (GLOBE NEWSWIRE) — More than 83% of primary care providers (PCPs) wish more of their patients would talk to them about mental health issues and concerns so they can provide better overall care, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN). Yet, results of the Spring 2022 survey showed only 1 in 4 patients were given a depression screening by their PCP. More than half of surveyed clinicians don’t think patients are aware that PCPs and nurse practitioners (NPs) are fully trained to diagnose and treat mental health conditions. “When a patient comes into my practice, they may not even be aware that their symptoms...

Continue reading

Lucira Health Announces National Launch of Lucira Connect Test-to-Treat Service

Lucira Connect – Fast, FREE Covid Care From Home Lucira is the 98% accurate, lab-quality at-home test you can rely on to tell you if you have Covid. Now with Lucira Connect, get one-touch access to a FREE telehealth session to assess care and treatment options without the need of visiting a doctor’s office.Lucira Connect – All You Need For Covid Care From Home The Lucira Covid-19 Test provides 98% accurate, lab-quality results in 30 minutes or less. Now with Lucira Connect, you also get FREE telehealth with a doctor to assess your Covid care options and get prescribed treatment, all from the comfort of home.Lucira Connect – A Faster, FREE Way to Covid Care Timing is everything when it comes to getting Covid treatment. The sooner you can get antivirals, the more effective they can be. Lucira Connect is the faster, FREE way to get...

Continue reading

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. The Company reported encouraging interim safety and immunogenicity data from the Phase 1/2a study of its personalized DNA-based immunotherapy, EVX-02. The results are summarized below. “We are thrilled to announce promising interim data from the first eight patients in our Phase 1/2a study of EVX-02. We believe that these results...

Continue reading

Formula Systems Reports Third Quarter and Nine Months 2022 Financial Results

OR YEHUDA, Israel, Nov. 17, 2022 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) (“Formula” or the “Company”), a global information technology group engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, today announced its results for the third quarter and nine-month period ended September 30, 2022. Financial Highlights for the Third Quarter Ended September 30, 2022Consolidated revenues for the third quarter ended September 30, 2022, increased by 8.5% to $636.3 million, compared to $586.3 million in the same period last year. Consolidated operating income for the third quarter ended September 30, 2022, increased by 14% to $57.5 million, compared to $50.5 million in the same period last...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.